LAWRENCE FONG, M.D.

Member, Scientific Advisory Board

Lawrence Fong, MD, is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at UCSF. He also co-directs the Parker Institute for Cancer Immunotherapy at UCSF and co-leads the Cancer Immunology Program in the Helen Diller Family Comprehensive Cancer Center. Dr Fong will serve as Co-Chair of Sutro’s Clinical Advisory Board and will also participate as a member of Sutro’s Scientific Advisory Board in his capacity as Co-Chair of the CAB.

Dr. Lawrence Fong is a medical oncologist who specializes in immunotherapy to care for cancer patients with an emphasis on genitourinary cancers (those involving the genital or urinary organs).

A physician-scientist, Dr. Fong studies new immunotherapies for cancer. He is internationally known for his work on multiple FDA-approved cancer immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has helped conduct numerous clinical trials and is the principal investigator on multiple research projects including those supported by the National Institutes of Health and private foundations. As the leader of UCSF’s Cancer Immunotherapy Program, he helps to develop new treatments through early-phase clinical trials of novel immunotherapies. His laboratory focuses on understanding why current treatments work in some patients but not others. Throughout his career, Dr. Fong has received several awards for his scientific contributions, including the National Cancer Institute’s Outstanding Investigator Award.

Dr. Fong earned his medical degree at Stanford University. He completed a residency in internal medicine at the University of Washington. He completed an oncology fellowship at Stanford Medicine.

Dr. Fong joined the UCSF faculty in 2001 and is the Efim Guzik Distinguished Professor in Cancer Biology. He has published more than 100 peer-reviewed scientific articles, numerous book chapters, and multiple patents. Dr. Fong has lectured nationally and internationally on cancer immunotherapy.